PQQ disodium salt, pyrroloquinoline quinone sodium salt; pyrroloquinoline quinone disodium salt, pyrroloquinoline benzoquinone sodium
CAS: 122628-50-6
Chemical Formula: C14H4N2Na2O8
MW: 374.17
Availability: R&D; Commercialization
⬤ CAS No. 122628-50-6
⬤ Packaging type：
20kg barrel；5kg barrel；1kg bag；500g bag
| Name | Pyrroloquinoline quinone disodium salt |
| CAS Number | 122628-50-6 |
| Molecular Formula | C14H4N2Na2O8 |
| Molecular Weight | 374.17 |
| Alias | Methoxatin disodium salt |
| Product Category | Dietary Supplement |
| Main Functions | Supports mitochondrial growth and development, Antioxidant properties, Improves brain health, cardiovascular health, and metabolic functions |
| Purity Specification | 99% |
| Appearance | Red-brown powder |
| Flash Point | 569.8 ºC |
| Solubility in Water | 6.16 mg/mL (16.46 mM) |
| Storage Conditions | 3 years at -20°C, Powder form |
| Storage Conditions | 2-8°C |
| Form | Solid |
| Color | Pink to red |
| Prohibited Use | For human use and treatment |
| Return Policy | Selleck offers a flexible return policy |
| Overview | The scientific name of PQQ is pyrroloquinoline quinone, which is a new cofactor that has the effects of treating heart disease, neurological diseases, protecting the liver, and maintaining mitochondrial function. |
| Uses | Pyrroloquinolin quinone disodium salt (PQQ-2Na) is a sodium salt derivative of pyrroloquinolin quinone (PQQ-2Na), which is the active ingredient of health products currently on the market. It has nerve growth factor induction activity and has a certain effect on Parkinson’s disease, and can prevent immune liver damage. |
| Target | Human Endogenous Metabolite |
| Biological activity | Pyrroloquinolinequinonedisodiumsalt is a redox cofactor, an anionic redox cycle quinone. It was originally isolated from the culture of methylophilic bacteria and is also present in mammalian tissues. Pyrroloquinolinequinonedisodiumsalt is an essential nutrient for mammals and is important for immune function. |
Exceptional Product Quality
“We have been sourcing pharmaceuticals from Tianming Pharmaceutical for several years now, and their product quality has consistently exceeded our expectations. Each batch undergoes rigorous testing, ensuring we receive only the highest quality products. This reliability has significantly contributed to our trust and satisfaction with their services. Highly recommended!”
June 15, 2023
Outstanding Technical Guidance
“The technical guidance provided by Tianming Pharmaceutical’s team has been invaluable to our research and development projects. Their experts are knowledgeable, responsive, and always willing to assist with detailed explanations and support. Their guidance has enabled us to optimize our processes and achieve remarkable results. We couldn’t ask for a better partner.”
June 15, 2023
Superior Service Experience
“Our experience with Tianming Pharmaceutical has been nothing short of excellent. Their customer service team is exceptionally responsive and dedicated to meeting our needs. From initial consultation to after-sales support, they have provided seamless, professional service. Their commitment to customer satisfaction is truly commendable.”
June 15, 2023
Precise Product Specifications
“Tianming Pharmaceutical has impressed us with their adherence to precise product specifications. Each order is meticulously packaged and delivered exactly as requested, ensuring that we receive products that perfectly meet our requirements. Their attention to detail and commitment to accuracy have made them a trusted supplier for our business.”
June 15, 2023
Orforglipron’s non-peptide scaffold (23 atoms) enables oral GLP-1 therapy via acid-stable triazole core, (R)-chlorophenyl chiral targeting, and pyridine N-oxide H-bonding. Tianming Pharma provides key intermediates for scalable synthesis.
We have made a major breakthrough in the production of orforglipron intermediates. We now offer a range of orforglipron intermediates with detailed information. Please contact us for more information to meet your pharmaceutical needs.
This article examines six pivotal trends reshaping the 2025 pharma intermediates sector: Asia’s manufacturing evolution, continuous production adoption, AI-driven R&D acceleration, ESG compliance pressures, nearshoring strategies, and biomanufacturing breakthroughs.
Leading provider of high-quality APIs and intermediates. Contact us for innovative solutions and expert support.
